JWH-077

JWH-077 is a synthetic cannabinoid that acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. It is part of the naphthoylindole family of compounds and was first synthesized by John W. Huffman and his team at Clemson University in the 1990s. JWH-077 is one of many synthetic cannabinoids that have been used in research to better understand the endocannabinoid system.

Chemical Structure and Properties

JWH-077 has the chemical formula C24H23NO and a molecular weight of 341.45 g/mol. Its structure consists of a naphthoyl group attached to an indole core, with a pentyl chain at the nitrogen atom of the indole. This structure is similar to other synthetic cannabinoids, such as JWH-018 and JWH-073, which also feature a naphthoylindole core.

Pharmacology

JWH-077 is a full agonist at both the CB1 and CB2 receptors, with a higher affinity for the CB1 receptor. The activation of these receptors by JWH-077 leads to effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. These effects include alterations in mood, perception, and cognition, as well as potential therapeutic effects such as analgesia and anti-inflammatory properties.

Legal Status

The legal status of JWH-077 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. In the United States, JWH-077 and other synthetic cannabinoids have been placed under Schedule I of the Controlled Substances Act, making their manufacture, distribution, and possession illegal without a license.

Research and Applications

JWH-077 has been used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. It has also been used as a reference compound in the development of new synthetic cannabinoids and in forensic analysis to identify synthetic cannabinoid use.

Health Effects and Risks

The use of JWH-077 and other synthetic cannabinoids can pose significant health risks. These compounds can produce severe adverse effects, including tachycardia, hypertension, hallucinations, and psychosis. The variability in potency and purity of synthetic cannabinoids further increases the risk of overdose and toxic reactions.

Also see

• Synthetic cannabinoids
• JWH-018
• Endocannabinoid system
• Cannabinoid receptor
• John W. Huffman